Catalent's deal with ALK-Abello will expand Zydis capacity

New Jersey, USA-based Catalent Pharma Solutions and Danish pharmaceutical company ALK-Abello A/S have signed an agreement that will enable a substantial increase in Zydis oral-dissolving tablet production capacity dedicated to the latter's immunotherapy products.

Under the accord, ALK-Abello will fund a new production line for current and future tablet-based allergy products, which will be based at Catalent's Swindon, UK, facility. Commercial production on the new line is currently expected to begin in 2010.

ALK-Abello has launched GRAZAX, a tablet-based vaccine against grass pollen allergy, using Catalent's innovative Zydis oral dissolving tablet technology, and the US firm is already producing the Zydis formulation of GRAZAX in Swindon.